{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-016970","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.897233+00:00","generated_at":"2026-06-26T12:51:15.986374+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emmaus Life Sciences FY2021 revenue $20.6M; net loss $15.9M vs prior-year net income","bullets":["Net revenue $20.6M, down 11% from $23.2M in 2020; sales volume steady but discounts hurt.","Operating loss $6.1M vs $32,000 loss in 2020; R&D and selling expenses increased.","Net loss attributable to common $15.9M ($0.32 per share) vs net income $1.4M ($0.03) in 2020.","Cash $2.3M at Dec 31, 2021; Endari added to Florida Medicaid preferred drug list, UAE approval obtained.","Licensed IRAK4 inhibitor from Kainos for cancer; telehealth partnership with UpScript launched."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-016970","json":"https://secwatch.observer/filing/0001213900-22-016970.json","markdown":"https://secwatch.observer/filing/0001213900-22-016970.md","text":"https://secwatch.observer/filing/0001213900-22-016970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390022016970/0001213900-22-016970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390022016970/ea157399-8k_emmauslife.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T12:51:15.986374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}